CCTG Clinical Trials
Public Trial Select
Member Trial Select
International research collaboration explores blood-based biomarkerUsing non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
June 26, 2019
It is almost here! The CCTG New Investigator Clinical Trials CoursePublished: June 26, 2019Category: Group updates  There is still time to register for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario. The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment. Read More |
Appointment of Dr. Alex Sun as Co-Chair of Lung Disease Site CommitteePublished: June 26, 2019Category: Group updates  Earlier this year Dr. Yee Ung stepped down from his position as the co-chair of the CCTG Lung Disease Site committee. The group convened a selection committee to choose a radiation oncologist as the new co-chair, over several months the committee solicited applications and interviewed several candidates. The members of the selection committee were: Drs. Penny Bradbury, Matthew Parliament, Andrea Bezjak, Yee Ung, and Joe Pater. Read More |
 Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include: Read More |
Publication - Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatmentsPublished: June 26, 2019Category: Publications  A secondary methodological analysis. Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Read More |
June 12, 2019
 IND238 (NCT03847649), A Phase II Study of Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity, has been centrally activated. Read More |
Revision 2 Good Clinical Practice training course updatedPublished: June 12, 2019Category: Group updates  The Office of Compliance and Oversight released an updated Good Clinical Practice training course, that includes Revision 2. The revised GCP training course is available for new members who have not yet trained in GCP. A GCP refresher module, including the Revision 2 updates, was created for members who have previously completed a GCP training course. GCP training will be valid for three years from the date of completion. This training is mandatory for all members conducting clinical trials per CCTG SOPs and in compliance with NIH policy. Read More |
CRA Volunteer Needed for the Breast, Gastrointestinal and Gynecologic Disease Site ExecutivePublished: June 12, 2019Category: Group updates  Clinical Research Associate (CRA) Volunteer Needed for the Breast, Gastrointestinal and Gynecologic Disease Site Executive! The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Breast, Gastrointestinal and Gynecologic Disease Site Committee Executives. Read More |
 At ASCO 2019 the landmark ENZAMET | CCTG PR17 (NCT02446405) clinical trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Findings, show that men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to men receiving standard treatment alone. Read More |